Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.

Matsuura S, Komeno Y, Stevenson KE, Biggs JR, Lam K, Tang T, Lo MC, Cong X, Yan M, Neuberg DS, Zhang DE.

Blood. 2012 Nov 8;120(19):4028-37. doi: 10.1182/blood-2012-01-404533. Epub 2012 Aug 23.

2.

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.

Harada Y, Harada H.

J Cell Physiol. 2009 Jul;220(1):16-20. doi: 10.1002/jcp.21769. Review.

PMID:
19334039
3.

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K, Shibata M, Mizuki M, Kanakura Y.

Leukemia. 2012 Feb;26(2):303-11. doi: 10.1038/leu.2011.202. Epub 2011 Aug 12.

PMID:
21836608
4.

Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.

Harada Y, Harada H.

J Cell Biochem. 2011 Feb;112(2):425-32. doi: 10.1002/jcb.22974.

PMID:
21268063
5.

AML1 mutations induced MDS and MDS/AML in a mouse BMT model.

Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T, Kitamura T.

Blood. 2008 Apr 15;111(8):4297-308. doi: 10.1182/blood-2007-01-068346. Epub 2008 Jan 11.

6.

Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.

Tsai SC, Shih LY, Liang ST, Huang YJ, Kuo MC, Huang CF, Shih YS, Lin TH, Chiu MC, Liang DC.

Clin Cancer Res. 2015 Aug 1;21(15):3541-51. doi: 10.1158/1078-0432.CCR-14-2203. Epub 2015 Apr 3.

7.

Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.

Harada H, Harada Y.

Crit Rev Eukaryot Gene Expr. 2005;15(3):183-96. Review.

PMID:
16390315
8.

Ectopic Runx1 expression rescues Tal-1-deficiency in the generation of primitive and definitive hematopoiesis.

Tornack J, Seiler K, Grützkau A, Grün JR, Onodera M, Melchers F, Tsuneto M.

PLoS One. 2013 Jul 29;8(7):e70116. doi: 10.1371/journal.pone.0070116. Print 2013.

9.

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.

Niimi H, Harada H, Harada Y, Ding Y, Imagawa J, Inaba T, Kyo T, Kimura A.

Leukemia. 2006 Apr;20(4):635-44.

PMID:
16467864
10.

A role for RUNX1 in hematopoiesis and myeloid leukemia.

Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, Kurokawa M.

Int J Hematol. 2013 Jun;97(6):726-34. doi: 10.1007/s12185-013-1347-3. Epub 2013 Apr 24. Review.

PMID:
23613270
11.

Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.

Sakurai M, Kunimoto H, Watanabe N, Fukuchi Y, Yuasa S, Yamazaki S, Nishimura T, Sadahira K, Fukuda K, Okano H, Nakauchi H, Morita Y, Matsumura I, Kudo K, Ito E, Ebihara Y, Tsuji K, Harada Y, Harada H, Okamoto S, Nakajima H.

Leukemia. 2014 Dec;28(12):2344-54. doi: 10.1038/leu.2014.136. Epub 2014 Apr 15.

PMID:
24732596
12.

Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.

Liao R, Xu Y, Chen M, Chen X, Zhan X, Sun J.

Hematology. 2013 Jul;18(4):191-7. doi: 10.1179/1607845412Y.0000000053. Epub 2013 Jan 3. Review.

PMID:
23321417
13.

Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.

Rajapaksa R, Ginzton N, Rott LS, Greenberg PL.

Blood. 1996 Dec 1;88(11):4275-87.

14.

Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.

Bluteau D, Gilles L, Hilpert M, Antony-Debré I, James C, Debili N, Camara-Clayette V, Wagner-Ballon O, Cordette-Lagarde V, Robert T, Ripoche H, Gonin P, Swierczek S, Prchal J, Vainchenker W, Favier R, Raslova H.

Blood. 2011 Dec 8;118(24):6310-20. doi: 10.1182/blood-2010-12-325555. Epub 2011 Jul 1.

15.
16.

Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Nick HJ, Kim HG, Chang CW, Harris KW, Reddy V, Klug CA.

Blood. 2012 Feb 9;119(6):1522-31. doi: 10.1182/blood-2011-02-338228. Epub 2011 Sep 21.

17.

RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.

Cammenga J, Niebuhr B, Horn S, Bergholz U, Putz G, Buchholz F, Löhler J, Stocking C.

Cancer Res. 2007 Jan 15;67(2):537-45.

18.

A novel retroviral mutagenesis screen identifies prognostic genes in RUNX1 mediated myeloid leukemogenesis.

Rae DT, Hocum JD, Bii V, Deeg HJ, Trobridge GD.

Oncotarget. 2015 Oct 13;6(31):30664-74. doi: 10.18632/oncotarget.5133.

19.

Runx1 isoforms show differential expression patterns during hematopoietic development but have similar functional effects in adult hematopoietic stem cells.

Challen GA, Goodell MA.

Exp Hematol. 2010 May;38(5):403-16. doi: 10.1016/j.exphem.2010.02.011. Epub 2010 Mar 3.

20.

Physician Education: Myelodysplastic Syndrome.

Yoshida Y.

Oncologist. 1996;1(4):284-287.

Supplemental Content

Support Center